KNSA (Kiniksa Pharmaceuticals International) Common Stock: $0.0 Mil (As of Mar. 2026)


KNSA Kiniksa Pharmaceuticals International PLC KNSA
50 GF Score
Price $64.53
GF Value $48.22
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Kiniksa Pharmaceuticals International Common Stock?

Kiniksa Pharmaceuticals International KNSA +2.62% 50 Common Stock is $0.0 Mil as of Mar. 2026. GuruFocus rates KNSA with a GF Score™ of 50/100 and a GF Value™ of $48.22 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Kiniksa Pharmaceuticals International's quarterly common stock stayed the same from Sep. 2025 ($0.0 Mil) to Dec. 2025 ($0.0 Mil) and stayed the same from Dec. 2025 ($0.0 Mil) to Mar. 2026 ($0.0 Mil).

Kiniksa Pharmaceuticals International's annual common stock stayed the same from Dec. 2023 ($0.0 Mil) to Dec. 2024 ($0.0 Mil) but then increased from Dec. 2024 ($0.0 Mil) to Dec. 2025 ($0.0 Mil).

Kiniksa Pharmaceuticals International Common Stock Historical Data

* Premium members only.

The historical data trend for Kiniksa Pharmaceuticals International's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kiniksa Pharmaceuticals International Common Stock Chart

Kiniksa Pharmaceuticals International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.02 0.02 0.02 0.02

Kiniksa Pharmaceuticals International Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.02 0.02 0.02
KNSA
50GF Score
Kiniksa Pharmaceuticals International PLC KNSA
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kiniksa Pharmaceuticals International Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.0 Mil mean?
Kiniksa Pharmaceuticals International (KNSA) has a Common Stock of $0.0 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Kiniksa Pharmaceuticals International and its competitors.
Is Kiniksa Pharmaceuticals International's Common Stock too high?
Kiniksa Pharmaceuticals International's current Common Stock is $0.0 Mil. Overall, Kiniksa Pharmaceuticals International has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kiniksa Pharmaceuticals International's Common Stock compare to INDV and AMRX?
Kiniksa Pharmaceuticals International's Common Stock of $0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Drug Manufacturers company?
A good Common Stock depends on the Drug Manufacturers industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Kiniksa Pharmaceuticals International and its competitors. Kiniksa Pharmaceuticals International's current Common Stock is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiniksa Pharmaceuticals International stock overvalued right now?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International (KNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is $48.22, compared to a current price of $64.53 — trading 33.8% above its estimated fair value. The current Common Stock is $0.0 Mil. Kiniksa Pharmaceuticals International's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Kiniksa Pharmaceuticals International (KNSA), the current Common Stock is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kiniksa Pharmaceuticals International (KNSA) Overvalued in 2026?

Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued. The current stock price of $64.53 is trading 33.8% above its estimated GF Value™ of $48.22. GuruFocus considers Kiniksa Pharmaceuticals International to be Significantly Overvalued.

Key valuation signals for KNSA:

  • Common Stock: $0.0 Mil
  • GF Value™: $48.22 vs. price of $64.53 (33.8% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the KNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kiniksa Pharmaceuticals International Business Description

Address 105 Piccadilly, Second Floor, London, GBR, W1J 7NJ
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
50GF Score

Get the complete analysis for KNSA

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$64.53
Price
$48.22
GF Value